维拉帕米逆转胰腺癌化疗耐药的研究

目的　探讨多药耐药蛋白P 170拮抗剂维拉帕米对胰腺癌细胞株化疗耐药的逆转作用。方法　采用RT PCR法对胰腺癌细胞株SW 1990和CAPAN 1中多药耐药基因MDR1mRNA的表达进行半定量分析 ;罗丹明外排试验检测胰腺癌细胞株中P 170的功能 ;MTT比色法评估胰腺癌细胞株对化疗药物的敏感性 ,并比较单纯化疗与化疗联合维拉帕米对其的疗效差异。结果　RT PCR检测结果显示MDR1mRNA在SW 1990中的表达丰度为 0 5 75 0± 0 0 76 4 ,在CAPAN 1中的表达丰度为 0 186 4± 0 0 5 36 ,两者具有显著差异 (P <0 0 1)。罗丹明外排试验表明 :SW1990阳性细胞百分数明显低于CAPAN 1(P <0 0 1) ;维拉帕米可使SW 1990阳性细胞百分数明显增加 (P <0 0 1)。MTT结果表明 :SW1990较CAPAN 1对ADM、MMC耐药 ;维拉帕米可部分逆转其对ADM和MMC的耐药性。结论　MDR1可能参与胰腺癌细胞株化疗耐药 ;中等剂量的维拉帕米联合化疗可逆转具有MDR1表型的人胰腺癌细胞株对ADM和MMC的耐药现象。

Reversal of chemo-resistance in pancreatic carcinoma by verapamil

Objective To assess the reversing effects of verapamil on chemo-resistance in pancreatic carcinoma. Methods The expression and function of MDR1 mRNA and P-170 were determined by RT-PCR and FCM. The chemo-resistance of 2 pancreatic carcinoma cell lines was assessed and the efficiency of chemotherapy compared between simple chemotherapy and combined one using verapamil by MTT. Results SW1990 cell line exhibited certain drug resistance to ADM and MMC compared with CAPAN-1. The resistance could be partly reversed by verapamil. Conclusions Moderate dose of verapamil can reverse chemo-resistance of pancreatic carcinoma cell line to ADM and MMC that might be related to MDR1.